ArticleFrontiers in immunology2016
NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells.
Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 45 citations in OpenAlex.
- Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.Journal for immunotherapy of cancer · 2017Trial
- Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours.Veterinary and comparative oncology · 2026Article
- Safety and Feasibility of InfusingbioRxiv : the preprint server for biology · 2026Article
- Natural killer cell dysregulation in polycystic ovary syndrome: immunometabolic and reproductive implication.Frontiers in immunology · 2026Review
- Canine cutaneous lymphoma of large granular lymphocytes non-B, non-T natural killer immunophenotype with cardiac, gastric and hepatic involvement.Brazilian journal of veterinary medicine · 2026Article
- Nanobody-based canine PD-L1-targeting immune checkpoint inhibitors for cancer therapy in dogs.Molecular therapy. Oncology · 2025Article
- The Future Exploring of Gut Microbiome-Immunity Interactions: From In Vivo/Vitro Models to In Silico Innovations.Microorganisms · 2024Review
- Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.Journal for immunotherapy of cancer · 2024Article
- Improved characterization and translation of NK cells for canine immunotherapy.Frontiers in veterinary science · 2024Review
- Missing a "Missing Self" Mechanism: Modeling and Detection of Ly49 Expression in Canine NK Cells.ImmunoHorizons · 2023Article
- Racing CARs to veterinary immuno-oncology.Frontiers in veterinary science · 2023Review
- Article
- Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response.Journal for immunotherapy of cancer · 2022Article
- Role of NK-Like CD8Infection and immunity · 2022Article
- Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.Frontiers in immunology · 2022Article
- There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment.Veterinary and comparative oncology · 2021Review
- Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.Cancers · 2021Article
- T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma.Frontiers in veterinary science · 2021Article
- Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma.Frontiers in veterinary science · 2021Article
- Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Canines spontaneously develop many cancers similar to humans - including osteosarcoma, leukemia, and lymphoma - offering the opportunity to study immune therapies in a genetically heterogeneous and immunocompetent environment. However, a lack of antibodies recognizing canine NK cell markers has resulted in suboptimal characterization and unknown purity of NK cell products, hindering the development of canine models of NK cell adoptive immunotherapy. To this end, we generated a novel antibody to canine NCR1 (NKp46), the putative species-wide marker of NK cells, enabling purification of NK cells for further characterization. We demonstrate that CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.